AAP
STRO icon

Arax Advisory Partners’s Sutro Biopharma STRO Stock Holding History

Arax Advisory Partners’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$531 Sell
16
-25
-61% -$780 ﹤0.01% 5012
2026
Q1 		$75 Buy
41
+38
+1,267% +$687 ﹤0.01% 3635
2025
Q4 		$35 Sell
3
-381
-99% -$3.62K ﹤0.01% 3977
2025
Q3 		$3.34K Buy
+384
New +$3.27K ﹤0.01% 2983
2024
Q4 		– Sell
-66
Closed -$2.27K – 2734
2024
Q3 		$2.27K Hold
66
– – ﹤0.01% 2021
2024
Q2 		$1.93K Buy
+66
New +$2.61K ﹤0.01% 1979

Other funds holding STRO

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Arax Advisory Partners's STRO Position: Q2 2026 in Review

Arax Advisory Partners reduced its Sutro Biopharma (STRO) stake by 61% in Q2 2026, selling an estimated $780 and leaving 16 shares worth $531. The position accounts for ﹤0.01% of the portfolio, ranked #5012.

Arax Advisory Partners first reported a position in STRO in Q2 2024 and has held it in 6 quarters since. The position peaked at $3.34K in Q3 2025. 100 funds tracked by Wall St. Rank hold STRO as of Q2 2026.

  • Arax Advisory Partners held 16 shares of Sutro Biopharma worth $531 as of Q2 2026.
  • Arax Advisory Partners sold 25 Sutro Biopharma shares in Q2 2026, an estimated $780.
  • Sutro Biopharma made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #5012 holding.
  • Arax Advisory Partners first reported a position in Sutro Biopharma in Q2 2024 and has held it in 6 quarters since.
  • Arax Advisory Partners's Sutro Biopharma position peaked at $3.34K in Q3 2025.
  • 100 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.